NCT05257408: An ongoing trial by Corcept Therapeutics
This trial is ongoing. It must report results 1 year from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05257408 |
|---|---|
| Title | A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 29, 2022 |
| Completion date | March 31, 2025 |
| Required reporting date | March 31, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |